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Abstract 
Clinical molecular imaging by use of PET and PET/CT is increasingly important in routine 
oncological practice worldwide. A vast majority of clinical PET investigations are performed 
with [
18F]-fluorodeoxyglucose (FDG), but there is a growing interest in novel molecular 
probes among scientists and clinicians. Beyond FDG, a small number of different tracers have 
been shown to be of clinical value. With a growing commercial interest in tracer development, 
many more are under investigation. This review provides some examples of clinical situations 
where tracers other than FDG have been found useful and an outlook towards technical and 
regulatory development needed to allow the full impact of clinical PET to benefit the individual 
patient. 
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Introduction 
Positron Emission Tomography (PET) is as old as 
computed tomography (CT), but only during the last 
decade has PET been regarded as a relevant clinical 
entity. This change is due to two fundamental issues, 
primarily: 1. evidence of the almost universal utility of 
[18F]-fluorodeoxyglucose (FDG) PET in the evaluation 
of cancers  [1, 2] and 2. a  dramatic improvement  in 
clinical acceptance and patient logistics when PET and 
CT were combined into a hybrid device. [3] 
A range of positron emitting isotopes is available 
for use in clinical imaging with PET, of which the bi-
ologically most relevant isotopes are carbon-11, oxy-
gen-15 and fluoride-18. Substituting a stable isotope 
with its positron-emitting counterpart in biologically 
interesting molecules provide tracers of endogenous 
substances or drugs with no or only minimal phar-
macodynamic  differences.  The  tracers  are  typically 
injected into the blood stream in microgram amounts 
and the PET scanner is able to detect and accurately 
quantify tracer concentrations at the picomolar level.  
When the radioactive isotope incorporated into 
the PET tracer decays, a positron is emitted and im-
mediately collides with an electron. The collision re-
sults in an annihilation of both particles and the for-
mation of two high-energy photons that leave the site 
of collision at angels of 180 degrees. The PET scanner 
is  built  to  detect  the  photons  in  coincidence,  disre-
garding all other signals as noise. When a sufficient 
number of decays have been detected and stored, a 
computer  converts  the  information  about  decay 
events into images, where the color of each pixel rep-
resents radioactivity concentration or some derivative 
thereof.  These  images  are  further  investigated  in 
dedicated work-stations, where the CT and PET im-
ages can be visualized interactively in a fused display. 
FDG is a non-metabolized glucose analog that is 
a substrate both for the dedicated glucose transporters 
on  the  cell  membrane  and  the  cytoplasmic  enzyme 
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hexokinase  responsible  for  phosphorylation.  After 
phosphorylation the FDG is not a substrate for further 
pathways and is effectively trapped in the cell. Many 
cancers  rely  on  glucose  for  energy  production  and 
growth  and  tend  to  have  enhanced  expression  of 
glucose transporters and hexokinase, resulting in an 
elevated  accumulation  of  FDG  when  studied  with 
PET in vivo. 
The clinical impact of FDG-PET/CT is perhaps 
most obvious in the evaluation of non-small cell lung 
cancer  (NSCLC)  and  is  currently  regarded  as  a 
first-line  requirement  for  optimal  patient  care.[4] 
There are several reasons for using FDG-PET/CT in 
the evaluation of cancer, as can be seen in Figure 1. 
The finding of a suspicious lung nodule in CT com-
bined with an elevated FDG uptake has a high sensi-
tivity  detecting  a  cancerous  growth  in  the  lesion 
(Figure 1, A). Such a patient needs urgent treatment. 
On the other hand, a similar lesion in CT associated 
with an absence of FDG uptake has a very high nega-
tive  predictive  value  (Figure  1,  B)  and  this  patient 
could be subjected to watchful waiting.  
In case the lung lesion is confined, the patient is 
potentially curable by surgery. However, lung cancer 
often  metastasizes  early.  For  this  reason,  modern 
FDG-PET/CT  imaging  evaluates  larger  parts  of  the 
body,  typically  from  the  base  of  the  skull  to  the 
mid-thighs,  and  has  a  very  high  sensitivity  for  de-
tecting  spread disease. The PET images show more 
metastatic  lesions  than  any  other  imaging  modality 
(Figure 1,C). 
 
Figure 1. Lung cancer. Transaxial images of CT (left) and FDG-PET/CT (right) in three different patients. A: A male smoker with 2 cm 
lump in left lung (red cross hair). With CT alone the risk of this lump being cancer is 50%. The lump has a very high FDG uptake, which 
is typical for fast growing cancers and the combined image indicates an 80% risk of cancer. B: A non-smoking female with a 1.5 cm lesion 
that has no FDG uptake (the large yellow area is the heart muscle). The negative predictive value of the combined image is 99%. C: CT with 
a bone window setting is negative for bone metastases. PET shows two small metastases with very intense uptake. This pattern indicates 
infiltrative growth in the bone marrow with minimal destruction of bone structure and might precede positive findings on CT alone by 
several months. Theranostics 2012, 2(5) 
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Use of FDG-PET/CT in staging of cancer 
While the benefits of FDG-PET/CT for detection 
and staging are most remarkable in lung cancer, sim-
ilarities in impact for several other cancer types have 
been sufficiently well documented and are now rou-
tinely considered obvious indications for PET. Table 1 
shows a list of reimbursable indications as granted by 
Medicare in the USA.[5] Coverage is granted for the 
majority  of  solid  cancers.  The  common  experience 
among many oncologists and imaging practitioners is 
that almost all solid tumors are sometimes relevant to 
scan and FDG-PET/CT often provides crucial infor-
mation  even  on  top  of  all  other  investigations  per-
formed. This experience has been integrated in clinical 
routines in some areas of the world, including many 
European  countries,  where  all  patients  with  solid 
tumors are potentially candidates for FDG-PET/CT at 
the discretion of the referring physician. In an effort to 
provide evidence for this common finding, a recent 
registry study in the US managed to collect data from 
close to 30 000 patients with malignancies other than 
those previously reimbursed.[2] When compiled, the 
data indicated that FDG-PET/CT had a major impact 
on subsequent patient care in approximately 30% of 
cases, irrespective of tumor type. This study was piv-
otal when Medicare decided to support a number of 
new indications in 2009.  
Treatment response  
PET  is  inherently  a  quantitative  technique, 
meaning  that  the  scanner  measures  radioactivity 
concentrations, not merely isotopic decays. The quan-
titative properties can be utilized in many different 
ways and is the foundation of the use of PET in bio-
medical research.[6] In the clinical routine situation, 
quantitation  provides  an  opportunity  to  compare 
tumor tracer uptake in serial measurements, for ex-
ample  before  and  after  treatment.  Assuming  that  a 
sufficient  decrease  in  FDG  uptake  early  after  treat-
ment  reflects  a  similar  and  sustained  reduction  in 
tumor growth, this technique could be used as a bi-
omarker of treatment effect. Recent years have seen a 
strong interest in investigating the potential clinical 
utility of this biomarker approach to serial imaging.[7] 
The most obvious example of success is in the evalua-
tion  of  lymphoma  treatment.[8]  Malignant  lympho-
mas are characterized by a very high FDG uptake and, 
similar to the case of lung cancer, FDG-PET/CT often 
upstage  patients  because  more  lesions  are  detected 
than with any other approach. Modern treatment is 
highly  effective  and  has  improved  survival  greatly, 
but the lumpy lymphoma lesions often heal with scar 
formation. These scars consist of fibrous tissue, dis-
appear slowly and cannot be distinguished from re-
sidual malignancy with CT or MRI alone. When the 
lymphoma  patient  is  scanned  after  treatment,  a  re-
sidual lump without any FDG uptake is a prognosti-
cally excellent sign, while elevated FDG uptake sig-
nals remaining viable tumor with minimal likelihood 
of cure unless treatment is changed.[8] An example of 
the sometimes dramatic changes in tumor FDG up-
take after successful treatment can be seen in Figure 2.  
Serial FDG PET for treatment evaluation as an 
early biomarker for outcome has been investigated in 
several cancer types, but no specific protocols have so 
far been established in clinical routine with interna-
tional  consensus,  apart  from  lymphoma.  Even  for 
lymphoma,  the  best  documented  disease  in  which 
treatment  evaluation  using  PET  is  considered  rele-
vant, multicenter studies are needed to optimize and 
refine  the  protocols.  Defining  optimal  protocols  for 
other malignancies is an area of intense interest and 
research, by some considered crucial for future drug 
development.[7, 9-11]  
 
Table 1. A list of indications for FDG-PET supported by 
the US Medicare system. CED: Coverage with Evidence 
Development. 
Tumor Type   Initial Treatment 
Strategy 
Subsequent 
Treatment 
Strategy 
Colorectal  Cover   Cover 
Esophagus  Cover  Cover 
Head &Neck (not Thyroid, 
CNS) 
Cover  Cover 
Lymphoma  Cover  Cover 
Non-Small Cell Lung  Cover  Cover 
Brain  Cover  CED 
Ovary  Cover  Cover 
Cervix  Cover/CED  Cover 
Smal Cell Lung  Cover  CED 
Soft Tissue Sarcoma  Cover  CED 
Pancreas (exocrine)  Cover  CED 
Testes  Cover  CED 
Breast   CED/Cover dis-
tant metastasis 
Cover 
Melanoma  Cover  Cover 
Prostate  Non-Cover  CED 
Thyroid  Cover  CED 
All other solid tumors  Cover  CED 
Myeloma  Cover  Cover 
All other cancers not listed 
herein 
CED  CED 
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Figure 2. FDG-PET/CT for staging and treatment evaluation in lymphoma. Combined coronal [18F]-FDG PET/CT images from 
a 25-year old woman, who was diagnosed with aggressive Non-Hodgkins Lymphoma. Prior to PET/CT the patient was known to have 
disease in the neck and mediastinum. The left image was obtained before treatment and showed extensive growth of tumors not only in 
the neck and mediastinum, but also in abdominal lymph nodes, bone marrow, liver and spleen. This image dramatically changed the disease 
stage and the associated treatment. The image to the right shows the same view after three courses of a standardized chemotherapy 
regime, typically given in 8 courses. The mediastinal lumps remain visible on CT, termed ”partial anatomical remission”, but neither these 
lumps nor any of the previously diagnosed lymphoma locations show pathological FDG uptake, a pattern of findings termed ”complete 
metabolic remission”. This finding after treatment is highly predictive of treatment success without any need of therapy changes. On the 
other hand, remaining FDG uptake in any of the known lumps is associated with a high likelihood of recurrence. 
 
 
External radiation therapy dose planning 
with FDG PET/CT 
Almost  half  of  all  cancer  patients  will  receive 
radiation therapy (RT) during the cause of treatment. 
RT can be given with a curative intent, adjuvant or for 
palliation. RT with curative intent, during which ra-
diation is often delivered daily during several weeks, 
aims to deliver enough dose to kill off all cancer cells. 
Adjuvant therapy is given to reduce the size of the 
tumor  prior  to  surgery  or  to  enhance  the  effects  of 
concomitant  chemotherapy.  Palliative  radiation 
therapy is given to alleviate symptoms such as pain 
from bone metastases.  
Dose planning is most often done based on CT 
images, in which the tumor is identified and manually 
outlined.  More  advanced  techniques  for  delivering 
dose  exist,  such  as  Intensity  Modulating  Radiation 
Therapy (IMRT), with which radiation can be distrib-
uted with an accuracy of approximately 1 mm. The 
goal for all types of RT is to deliver as much energy to 
the cancer cells as possible, while sparing the normal 
tissues. 
FDG  PET/CT  is  useful  in  RT  planning  in  two 
different  ways.  First,  in  some  cancers,  such  as 
head-and-neck cancer and lung cancer, it is now clear 
that omitting whole-body FDG PET/CT prior to RT 
with curative intent could result in up to 10% of cases 
receiving futile treatment  because of metastatic dis-
ease being more widespread than perceived from CT Theranostics 2012, 2(5) 
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or MRI images alone.[12] Second, the PET images can 
provide  additional  information  about  the  extent  of 
local  cancer  growth.  This  is  seen  for  example  in 
head-and-neck cancer, where diffuse growth is seen 
by PET outside the solid tumor demarcation seen on 
CT and should result in a larger volume being irradi-
ated.[13] Or when only a smaller part of the perceived 
solid  tumor  actually  contains  metabolically  active 
cancer, which is commonly seen in lung cancer, where 
a large fraction of the tumor outlined on CT can be 
due to atelectasis (collapsed lung tissue after airway 
closure).[14]  
Beyond FDG: a world of tracers 
Development  in  molecular  imaging  requires  a 
network of specialists in several fields of science, but 
the full scope of opportunities is realized through the 
discipline of radiochemistry. A huge number of PET 
tracers  have  been  characterized  and  investigated  in 
human trials.[15] Many of these tracers have provided 
important information on specific aspects of the bio-
chemistry of the living organism. Only a small frac-
tion of previously developed tracers have been found 
useful in clinical diagnostic services, but the number 
is  increasing.  There  is  currently  an  exponential 
growth in the use of molecular imaging in many fields 
of  biological  research,  providing  opportunities  for 
commercial  interests  and  easier  access  for 
non-academic sites. A number of tracers are available 
from centralized production facilities and used clini-
cally in remote centres  within transportation range. 
Some  tracers  are  made  available  through  pre-made 
cassettes  that  are  mounted  and  used  locally  with 
standardized synthesizer production units.  
There  has  been  a  focus  on  establishing  tracers 
labeled  with  fluorine-18  for  clinical  use,  while  the 
more versatile isotope carbon-11 has been put to use 
for  labeling  tracers  in  academic  projects  and  drug 
development.  Recently,  the  use  of  generator-based 
radioisotope  production  has  seen  renewed  interest 
with  the  clinical  introduction  of  gallium-68-based 
labeling  of  somatostatin  analogs.[16]  Many  other 
peptides  and  macromolecules  can  be  labeled  with 
[68Ga],  but  have  so  far  not  reached  clinical  matura-
tion.[17]  
Some  long-lived  isotopes  are  currently  consid-
ered  for  clinical  PET  imaging.  [124I]-iodide  can  sub-
stitute  the  single  photon  emitting  equivalents  ([123I] 
and [131I] in evaluation of thyroid disease.[18] Mac-
romolecules are difficult to study with PET and the 
traditional  short-lived  isotopes  because  of  the  slow 
pharmacodynamics.  When  large  molecules,  such  as 
antibodies  and  fragments  thereof,  are  radiolabeled 
with isotopes of sufficiently long half-lives they could 
potentially  be  used  with  PET  imaging  many  hours 
after injection, at a time when only the tracer bound to 
the specific target remains in the tissue.[19]  
Radiotracers in clinical use with PET can be cat-
egorized in several different ways, depending on la-
beling, access and biological mechanisms of uptake, 
etcetera.  One  useful  biological  denominator  is 
whether the tracer identifies processes that are highly 
specific or integrative. Highly specific probes bind to 
a singular target, such as a receptor or enzyme. Such 
probes  are  typically  used  for  imaging  of  upstream 
targets that are unique expressed in association with a 
certain disease. An integrative probe identifies a gen-
eral  biological  activity  that  is  common  for  several 
parallel  processes  in  the  organism,  such  as  protein 
synthesis, energy metabolism or tissue perfusion. Ta-
ble 2 provides a list of some tracers that have been 
found clinically useful in our centre, an academic in-
stitution  with  a  strong  focus  on  radiochemistry  de-
velopment, or have been made commercially availa-
ble elsewhere.  
 
Table 2. A list of some clinically useful PET tracers. 
Tracer  Diagnostic relevance of uptake mechanism 
General biological activity (downstream markers) 
[18F]-fluorodeoxyglucose  The signal is proportional to glucose uptake and phosphorylation. Glucose is the major carbon donor for 
energy production and replenishment of macromolecule production in many organs and many cancers. 
1-[11C]-acetate  The smallest unit of carbon distribution. Initial uptake is proportional to blood flow. Retention is due to 
intracellular trapping as [11C]-acetyl-CoA, which is converted to [11C]-CO2 in oxidative metabolism or con-
sumed in liponeogenesis. Useful in investigations of cardiac physiology and for detection of some cancers, 
mainly prostate carcinoma. 
[18F]-fluoro-thymidine  A non-metabolized analog of thymidine, the only DNA-specific nucleotide. Signal is proportional to pro-
liferative activity in several cancer types, including astrocytomas and lung cancer. The tracer enters the cell 
through distinct thymidine transporters and is phosphorylated, which results in trapping.  
[11C]-L-methionine  Uptake and metabolism is similar to the endogenous molecule, an essential amino acid. Signal is propor-
tional to amino acid uptake and protein synthesis. Uptake is generally elevated in tissues with high anabolic Theranostics 2012, 2(5) 
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metabolism, such as glands, bone marrow and many cancers. Mainly used for brain tumor imaging. Several 
other radiolabeled amino acids are also in clinical use. 
[11C]-choline  Uptake is through membrane bound choline-transporters. Intracellular retention is due to phosphorylation 
and incorporation into phospholipids, to a large extent used to replenish fatty membranes. Membrane 
formation is linked to proliferation. Clinically used in prostate cancer imaging.  
Several cholin-analogs labeled with [18F] exist, the uptake mechanism being the same as for the carbon-11 
labeled tracer, but without the formation of phospholipids. 
[18F]-fluoride  Fluoride, when available, substitutes phosphate in the formation of bone mineral. Uptake and retention of 
the basic isotope is proportional to bone blood flow and bone mineral formation. Clinically used to study 
and diagnose skeletal diseases, mainly bone metastases. 
[15O]-water  Water is freely diffusible in all tissues. When used as a PET tracer, the rate of radioactive water flux is di-
rectly proportional to tissue perfusion, the nutritive portion of blood flow. Perfusion is important in many 
clinical scenarios and directly diagnostic in investigations of the heart and brain. 
Specific targeting (upstream markers) 
[11C]-metomidate  Specifically acts as an antagonist to beta-hydroxylase, a key enzyme in adrenocortical steroid synthesis. 
Clinically used to visualize tumors of adrenocortical origin. 
[11C]-5-hydroxytryptophan  Hydroxytryptophan is the key substrate for the enzyme Dopa decarboxylase in serotonin production. 
Metabolic accumulation of this tracer is highly upregulated in most tumors of neuroendocrine origin, spe-
cifically the carcinoids. 
[18F]-DOPA  Radiolabeled DOPA accumulates in dopaminergic presynaptic neurons and in tumors of neuroendocrine 
origin. Used to study and diagnose Parkinsonian syndromes and for visualization of neuroendocrine tu-
mors. 
[11C]-meta-hydroxyephedrine  A non-metabolized analog of norepinephrine. Accumulates in presynaptic vesicles of norepinephric syn-
apses. The signal is proportional to regional sympathetic activity. Used clinically in studies of cardiac in-
nervation and for detecting tumors originating from sympathetic tissues (pheochromocytomas, paragan-
gliomas). 
[68Ga]-DOTA-TOC  Radiolabeled somatostatin analogs are used in visualization and treatment of neuroendocrine tumors, 
specifically the carcinoids. Analogs labeled for use with PET have a higher sensitivity than the more com-
mon [111In]-labeled variants and are currently favored in clinical practice. 
[18F]-RGD-binding peptides  A number of peptides that bind to the RGD motif of the αvβ3 integrin have been labeled with [18F]. The 
integrin is co-expressed with the VEGF receptor during neoangiogenesis, the formation of new blood ves-
sels.  
[11C]-flumazenil  Flumazenil is a registered drug that acts as a partial agonist to benzodiazepines on the GABA-A receptor in 
the central nervous system. Clinically the drug is used as an antidote in sedative intoxication. As a tracer it 
is used to identify and locate brain abnormalities prior to surgery in patients with treatment-refractory 
epilepsy. 
[11C]-PIB  Pittsburgh compound B (“PIB”) binds to amyloid, a waste protein accumulating in the brains of patients 
with Alzheimer's disease. Currently used to enrich trials of anti-amyloid treatments by helping identify 
patients with substantial brain amyloid. A few reports indicate an opportunity to document changes in 
brain amyloid load quantitatively. There are several [18F]-labeled amyloid tracers in clinical trials. 
 
 
There are several examples of specific tracers al-
ready  in  clinical  use.  Figure  4  shows 
[11C]-5-hydroxytryptophan uptake in two very small 
bone metastases in a patient with a known carcinoid 
tumor. 5-Hydroxytryptophan is the precursor of ser-
otonin. The converting enzyme 5-hydroxytryptophan 
decarboxylase is highly expressed in the majority of 
tumors with neuroendocrine origin.[20] After evalu-
ating more than 1000 patient scans, it has been con-
firmed that no other tumor type or pathological pro-
cess have any extensive expression of the enzyme. As 
such, focal uptake of this tracer in the bones can only 
be  explained  by  metastases  from  a  neuroendocrine 
tumor.  With  experience,  a  tool  like  this  sometimes 
obviates the need for additional histopathology and 
the referring doctor moves directly towards relevant 
therapy.  
Scaling up: from a FDG-PET facility to a 
molecular imaging centre 
As the field of molecular imaging grows, there 
will  be  a  need  for  continuous  specialization  and 
training  for  many  different  types  of  experts.  The 
amount of information potentially available for eval-
uating  and  making  treatment  decisions  for  a  single 
patient will require teams of specialists. Clinically, the 
imaging expert will move from mainstream radiology 
focusing on morphology and structure towards a sit-
uation where imaging with multiple tracers is availa-
ble on top of a daunting amount of radiological im-Theranostics 2012, 2(5) 
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aging tools. Interpolating information from different 
biological  systems,  morphology,  upstream  and 
downstream markers will require training in molec-
ular  medicine,  pharmacology,  physiology  and  anat-
omy/radiology.  
Radiochemists  are  working  in  the  interface  of 
innovation and regulatory demands that tend to in-
crease over time. The major cost for a full scale mo-
lecular  imaging  centre  is  related  to  radiochemistry, 
including cyclotron services, which need to be taken 
into account early during planning. There is a defini-
tive  lack  of  radiochemists  with  skills  in  the  area  of 
tracer development and  many  more are needed for 
the field to continue to grow. 
 
 
Figure 3. Some tracers used for diagnosis in oncology in one PET Center. Numerous PET tracers have been investigated for 
clinical utility worldwide. For a few of these there are at least some evidences for patient benefit, supporting routine use in selected patient 
groups. This collage shows a number of the tracers in clinical routine use locally at the PET Centre of Uppsala University hospital. From 
top left to bottom right: [18F]-FDG is the universal tracer for evaluating the growth pattern and aggressiveness of a tumor.[1] The image 
shows a patient with an exocrine pancreatic cancer. [68Ga]-Gallium-DOTA-TOC is a somatostatin analog used for evaluating so-
matostatin-receptor-positive  tumors  of  neuroendocrine  origin.[16]  Shown  is  a  liver  metastasis  from  a  mid-gut  carcinoid  tumor. 
[11C]-5-Hydroxytryptophan is probably the most sensitive tracer for detection of neuroendocrine tumors.[20] This patient had a 5 
mm metastasis in the pericardium from an endocrine pancreatic tumor, confirmed at surgery. [18F]-Fluoride is helpful in detection of 
bone metastases.[29] [11C]-L-Methionine is a tracer of the endogenous essential amino acid and has a high uptake in many tumors. It is 
primarily used for brain tumor imaging,[30] but is also used as a last resort when trying to locate a parathyroid tumor [31]as shown in the 
image. [11C]-Metomidate binds selectively to the enzyme beta-hydroxylase, which is expressed exclusively in adrenal cortex. The tracer 
is  used  to  detect  tumors  of  adrenocortical  origin.[32]  The  image  shows  recurrence  of  an  adrenocortical  carcinoma. 
[11C]-meta-Hydroxyephedrine has a very high retention in sympathetically innervated tissues and is useful both for studying cardiac 
innervation and paragangliomas, especially in pheochromocytomas.[33] The image shows a patient with a left-sided pheochromocytoma. 
1-[11C]-acetate has a use in research of cardiac function[34] and as a general tracer for detection of highly differentiated tumors, 
primarily prostate carcinomas.[35] The image shows a large lymph node metastasis of prostate carcinoma. Theranostics 2012, 2(5) 
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Figure 4. A sagittal [11C]-5-Hydroxytryptophan PET/CT sectioning the spine in a patient referred for follow-up after treatment for a 
carcinoid tumor. Because of the specificity of the tracer, the very intense uptake in the millimeter-sized spinal lesions is highly suspicious 
for bone metastasis. 
 
Developing clinical molecular imaging, the 
near future 
In  a  few  years,  FDG-PET/CT  has  become  a 
standard tool for evaluating cancer patients. The use 
of FDG is likely to increase as evidence amounts re-
garding new indications. Similarly, a number of trac-
ers  for  general  biological  activity  have  been  made 
available  in  countries  where  regulatory  authorities 
accept the use of radiopharmaceuticals on the refer-
ring doctor's discretion. A range of proprietary tracers 
are currently in late phase clinical trials with the aim 
of making them commercially available. Some of the-
se  will  indicate  an  evolution  in  terms  of  diagnostic 
accuracy,  compared  to  less  advanced 
technologies.[21]  Other  novel  tracers  will  be  used 
primarily  to  stratify  patients  for  targeted 
therapies.[22-24]  
In  societies  that  accept  prescription  of 
GMP-made  radiopharmaceuticals  on  a 
”named-patient”-base, novel tracers will have an op-
portunity to contribute already in early clinical trials. 
On  the  other  hand,  if  no  commercial  entities  docu-
ment and manufacture tracers or kits for tracer pro-
duction for more widespread access, the new tracers 
cannot be introduced into general guidelines.  
Regulatory  authorities  are  currently  regarding 
radiopharmaceuticals  along  the  same  line  as  thera-
peutic drugs, in spite of the fact that PET tracers are 
injected in amounts of a few micrograms, often at a 
single occasion.[25, 26] There has been a number of 
years  where  no  new  radiopharmaceuticals  received 
marketing  authorization.  In  the  USA,  the  FDA  au-
thorized Capromab Pendetide (Prostascint) in Octo-
ber 1996. Not until January 2011 did another radio-
pharmaceutical,  [123I]-Ioflupane  (DATSCAN),  gain Theranostics 2012, 2(5) 
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authorization. Some authorities now suggest a trend 
towards  scrutinizing  the  barriers  for  approval  of 
compounds that are given in trace amounts.[27] The 
incentives for innovations and development appear to 
have been increased in recent years and several com-
panies now have novel PET tracers in late phase tri-
als.[22, 28]  
In  conclusion,  clinical  PET  is  increasingly  im-
pacting health care and helps stratify individual pa-
tient treatments. The use of FDG continues to grow, 
many other PET tracers are in small-scale use in aca-
demic centers and some are approaching a potential 
market authorization and more widespread use. 
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